A phase I/II study of the combination of lapatinib and oral vinorelbine in HER2 positive metastatic breast cancer

被引：0
|
作者：
Chen, T. W-W
Yeh, D-C
Chao, T-Y
Lin, C-H
Chow, L. W-C
Hsieh, Y-Y
Huang, S-M
Cheng, A-L
Huang, C-S
Lu, Y-S
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Taichung Vet Gen Hosp, Taichung, Taiwan
[3] Taipei Med Univ, Div Hematol & Oncol, Shuang Ho Hosp, New Taipei, Taiwan
[4] UNIMED Med Inst, Comprehens Ctr Breast Dis, Wan Chai, Hong Kong, Peoples R China
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P4-14-23
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-14-23
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)
    Gomez, H.
    Neciosup, S.
    Tosello, C.
    Mano, M.
    Bines, J.
    Ismael, G.
    Santi, P. X.
    Pinczowsky, H.
    Neron, Y.
    Fanelli, M.
    Fein, L.
    Sampaio, C.
    Lerzo, G.
    Capo, A.
    Zarba, J. J.
    Blajman, C.
    Varela, M. S.
    Martinez-Mesa, J.
    Werutsky, G.
    Barrios, C. H.
    CANCER RESEARCH, 2013, 73
  • [32] Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: A phase I/II study
    Cals, L
    Nouyrigat, P
    Valenza, B
    Pedinelli, FJ
    Juin, P
    ONCOLOGY, 2004, 67 (3-4) : 257 - 261
  • [33] SAFETY AND TOLERABILITY OF LAPATINIB IN COMBINATION WITH VINORELBINE (N) AND CAPECITABINE (C) AS SECOND LINE TREATMENT IN PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER (MBC)
    Bisagni, G.
    Bologna, A.
    Moretti, G.
    Gnoni, R.
    Boni, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 113 - 113
  • [34] A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer
    Lucas Bayo-Calero, Juan
    Mayordomo, Jose I.
    Salnchez-Rovira, Pedro
    Perez-Carrion, Ramon
    Illaramendi, Jose J.
    Garcia-bueno, Jose M.
    Gonzalez-Flores, Encarnacion
    Crespo, Carmen
    Ramos-Vazquez, Manuel
    Garcia-Palomo, Andres
    Ruiz-Borrego, Manuel
    de la Haba, Juan
    Gomez-Bernal, Amalia
    Yubero-Esteban, Alfonso
    CLINICAL BREAST CANCER, 2008, 8 (03) : 264 - 268
  • [35] Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
    Ma, Fei
    Ouyang, Quchang
    Li, Wei
    Jiang, Zefei
    Tong, Zhongsheng
    Liu, Yunjiang
    Li, Huiping
    Yu, Shiying
    Feng, Jifeng
    Wang, Shusen
    Hu, Xichun
    Zou, Jianjun
    Zhu, Xiaoyu
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (29) : 2610 - +
  • [36] A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer
    Stravodimou, Athina
    Voutsadakis, Ioannis A.
    ANTICANCER RESEARCH, 2019, 39 (07) : 3295 - 3301
  • [37] Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
    Chan, Arlene
    Shannon, Catherine
    de Boer, Richard
    Baron-Hay, Sally
    Redfern, Andrew
    Bauwens, Astrid
    Craft, Paul
    Webb, Suzanne
    Townsend, Amanda
    Kotasek, Dusan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (04) : 368 - 375
  • [38] Phase II study of lapatinib in combination with vinorelbine, as first- or second-line therapy in women with HER2-overexpressing metastatic breast cancer
    Chew, Helen K.
    Schwartzberg, Lee Steven
    Badarinath, Suprith
    Rubin, Peter
    Shumaker, Grace
    Daugherty, James P.
    DeSilvio, Michelle
    Mahoney, Janine M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] GEP01: A phase I pharmacokinetic study of lapatinib and iv vinorelbine in the treatment of HER2-positive locally advanced or metastatic breast cancer
    Rezai, Keyvan
    Isambert, Nicolas
    Brain, Etienne
    Dalenc, Florence
    Urien, Salk
    Dieras, Veronique
    Vanlemmens, Laurence
    Jimenez, Marta
    Roche, Henri
    Tresca, Patricia
    Fumoleau, Pierre
    Lokiec, Francois
    CANCER RESEARCH, 2011, 71
  • [40] Final Results of a Phase II Study of the Combination of Oral Vinorelbine (NVBo), Capecitabine (X) and Trastuzumab (H) in HER2-positive Metastatic Breast Cancer (MBC)
    Petruzelka, L.
    Ganju, V.
    Conte, P. F.
    Tubiana-Mathieu, N.
    Majois, F.
    Espie, M.
    Llombart, A.
    Gil Gil, M.
    Villanova, G.
    Chan, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S110 - S110
12345